Not all sufferers with CLL demand therapy. Inspite of all new developments, the iwCLL nonetheless endorses watchful observation for sufferers with asymptomatic disease.86 This advice is predicated on not less than two randomized trials comparing observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Also… Read More